Investment Thesis
Pre-revenue biotech company with negative $47.2M net income and $37.4M quarterly cash burn, resulting in approximately 2.2 years of runway at current burn rate. While improving diluted EPS suggests operational progress, the company lacks revenue generation and remains entirely dependent on clinical trial success with no near-term path to profitability.
Strengths
- Positive cash position of $83.8M provides near-term operational runway
- Zero debt burden reduces financial risk and leverage
- Diluted EPS improved 17.2% year-over-year, indicating cost management improvements
Risks
- Zero revenue with no visibility to near-term commercialization
- Quarterly cash burn of $37.4M leaves limited runway; dependent on continued financing
- Substantial liabilities of $254.4M relative to stockholders equity of $119.2M
- Entirely dependent on clinical trial outcomes; binary execution risk inherent in biotech development
Key Metrics to Watch
- Quarterly cash burn rate trend and cash runway extension
- Clinical trial progression, FDA milestone achievements, and regulatory pathway clarity
- Capital efficiency metrics and path to revenue generation from product candidates
Financial Metrics
Revenue
N/A
Net Income
-47.2M
EPS (Diluted)
$-0.17
Free Cash Flow
-37.7M
Total Assets
373.6M
Cash
83.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-39.6%
ROA
-12.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.29x
Quick Ratio
1.29x
Debt/Equity
0.00x
Debt/Assets
68.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:14:37.415485 |
Data as of: 2026-03-31 |
Powered by Claude AI